Following the CDC’s major revisions to the US childhood immunization schedule, Noel T. Brewer, PhD, distinguished professor ...

The Go for Bold initiative, which aims to help individuals in Washington County, Maryland, lose 1 million lb by 2030, serves as a successful, replicable model for community-wide health improvement. In ...

A medically trained LLM screened 1476 EMR records in one week, synthesizing structured variables and free-text notes to ...

Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.

Medicaid expansion correlates with lower breast cancer mortality, yet non-Hispanic Black women and lowest-income neighborhoods show limited or adverse gains without structural access interventions.

Food insecurity was defined as any house that had 3 or more food-insecure conditions. Households that had a household income lower than 185% of the federal poverty line were considered to be ...

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off. Drawing on global data, Toska examined HIV incidence ...

The Go for Bold initiative, which aims to help individuals in Washington County, Maryland, lose 1 million lb by 2030, serves as a successful, replicable model for community-wide health improvement.

Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar. The panelists were Lindsay Bealor Greenleaf, JD, MBA, head of market access policy ...

Coverage denials and prior authorization delays can compromise timely treatment, creating clinical deterioration and compounding financial toxicity as care escalates. Broadened semaglutide eligibility ...

In hormone receptor (HR)–positive, HER2-negative advanced breast cancer, starting CDK4/6 inhibitors (CDK4/6i) in the first line of therapy did not improve overall survival (OS) compared with reserving ...

Adjusted analyses associated overestimation with nearly doubled 2-year mortality (aHR 1.98; 95% CI, 1.04-3.77). Differences in advanced-therapy receipt did not explain the mortality signal, suggesting ...